“Twitching” and Stiffness in POLG1 Mutation Carriers: Red Flag or Red Herring?

Funding

Ethical Compliance Statement: Approval of an institutional review board was not required for this work. Written consent for publication was obtained from the patients. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this work is consistent with those guidelines. Funding Sources and Conflict of Interest: No specific funding was received for this work and the authors declare that there are no conflicts of interest relevant to this work. Financial Disclosures for the Previous 12 Months: M.G.P. is is supported by the Else Kröner‐Fresenius Foundation. S.T. is supported by Deutsche Forschungsgemeinschaft (DFG): SFB 936–project C5. T.B. reports honoraria from Pharm Allergan, Ipsen Pharma, and Merz Pharmaceuticals. Consultant for Pharm Allergan and Merz Pharmaceuticals. He received a grant from the DFG (FG2494). G.G.K. declares that there are no additional disclosures to report. A.M. reports commercial research support from Pharm Allergan, Ipsen, Merz Pharmaceuticals, and Actelion; honoraria for lectures from Actelion, GlaxoSmithKline, Desitin, and Teva; support from Possehl‐Stiftung (Lübeck, Germany), Margot und Jürgen Wessel Stiftung (Lübeck, Germany), Tourette Syndrome Association (Germany), Interessenverband Tourette Syndrom (Germany), and CHDI; academic research support from DFG projects 1692/3‐1, 4‐1, SFB 936, and FOR 2698 (project numbers 396914663, 396577296, 396474989), and Innovationsausschuss of the Gemeinsamer Bundesausschuss: Translate NAMSE (structural support for the Lübeck Center for Rare Diseases); and royalties for the book Neurogenetics (Oxford University Press).